Patient Satisfaction with CIMZIA


Journal

Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864

Informations de publication

Date de publication:
04 2020
Historique:
received: 06 12 2019
pubmed: 4 3 2020
medline: 15 12 2020
entrez: 4 3 2020
Statut: ppublish

Résumé

The CIMZIA Eligible patients with rheumatoid arthritis (RA), axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) were at least 18 years of age and initiated onto the CZP PFP. Routine self-injection training and support were provided by trained specialist nurses. Patient experience (pain and skin reactions, confidence, satisfaction, and ease of use) was evaluated at visits 1-3 using an amended version of the self-injection assessment questionnaire (SIAQ) v2.0. Nurse and patient feedback on the training materials, and nurse opinions on patient self-injection after self-injection at visit 1, were also collected. Of 355 patients invited to participate, 196 provided informed consent and 79 participated in all three visits. Patients generally found the CZP PFP easy to use, and self-confidence and satisfaction were high. From visit 1 to visit 3, there was a numerical trend towards improvement in all three aspects of patient experience, most notably in both confidence and satisfaction. After self-injection at visit 1, confidence around safe patient self-injection was higher among nurses than among patients. Meanwhile, "pain and skin reactions" remained low at all visits. Patients thought the training materials contained sufficient information and were easy to understand and useful. After training, patients generally found the device easy to use and showed high confidence and satisfaction with self-injection. Some patients may have been competent (based on nurse opinion), but initially lacked self-confidence. Increasing self-injection experience, together with patient training and continued support, may have facilitated high patient confidence and satisfaction, thereby potentially overcoming some of the barriers to self-injection.

Identifiants

pubmed: 32124272
doi: 10.1007/s12325-020-01257-6
pii: 10.1007/s12325-020-01257-6
pmc: PMC7140744
doi:

Substances chimiques

Antirheumatic Agents 0
Certolizumab Pegol UMD07X179E

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

1522-1535

Références

Lyseng-Williamson KA. Certolizumab pegol administration devices: a profile of their use and usability. Drugs Ther Perspect. 2017;33:515–22.
doi: 10.1007/s40267-017-0446-2
Marengo MF, Suarez-Almazor ME. Improving treatment adherence in patients with rheumatoid arthritis: what are the options? Int J Clin Rheumtol. 2015;10:345–56.
doi: 10.2217/ijr.15.39
Schwartzman S, Morgan GJ Jr. Does route of administration affect the outcome of TNF antagonist therapy? Arthritis Res Ther. 2004;6:S19–23.
doi: 10.1186/ar996
Domanska B, Stumpp O, Poon S, Oray S, Mountian I, Pichon C. Using patient feedback to optimize the design of a certolizumab pegol electromechanical self-injection device: insights from human factors studies. Adv Ther. 2018;35:100–15.
doi: 10.1007/s12325-017-0645-1
Keininger D, Coteur G. Assessment of self-injection experience in patients with rheumatoid arthritis: psychometric validation of the Self-Injection Assessment Questionnaire (SIAQ). Health Qual Life Outcomes. 2011;9:2.
doi: 10.1186/1477-7525-9-2
Sheikhzadeh A, Yoon J, Formosa D, Domanska B, Morgan D, Schiff M. The effect of a new syringe design on the ability of rheumatoid arthritis patients to inject a biological medication. Appl Ergon. 2012;43:368–75.
doi: 10.1016/j.apergo.2011.05.014
European Medicines Agency. Annex 1: summary of product characteristics (CIMZIA). 2019. https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001037/WC500069763.pdf . Accessed Jun 2019.
UCB Press Release: UCB announces the approval of CIMZIA® (certolizumab pegol) for moderate-to-severe plaque psoriasis, representing an important new option for patients in the US. https://www.ucb.com/stories-media/Press-Releases/article/UCB-Announces-the-Approval-of-CIMZIA-certolizumab-pegol-for-Moderate-to-Severe-Plaque-Psoriasis-Representing-an-Important-New-Option-for-Patients-in-the-U-S . Accessed Aug 2018.
UCB: UCB receives positive EU CHMP opinion for CIMZIA
Rheumatoid Arthritis News: Cimzia AutoClicks refilled pen for RA, other types of arthritis, now available in UK. https://rheumatoidarthritisnews.com/2016/10/26/cimzia-autoclicks-prefilled-pen-rheumatoid-arthritis-ra-now-available-uk/ . Accessed Apr 2018.
UCB and its design partners OXO win coveted design award for Cimzia
Domanska B, VanLunen B, Peterson L, Mountian I, Schiff M. Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis. Expert Opin Drug Deliv. 2017;14:15–22.
doi: 10.1080/17425247.2016.1256283
BHBIA. 2019. Legal and ethical guidelines for healthcare market research: your essential guide. https://www.bhbia.org.uk/assets/Downloads/Guidelines/bhbia_legal_and_ethical_guidelines_august_2019_v3fv.PDF . Accessed Jan 2020.
Schiff M, Saunderson S, Mountian I, Hartley P. Chronic disease and self-injection: ethnographic investigations into the patient experience during treatment. Rheumatol Ther. 2017;4:445–63.
doi: 10.1007/s40744-017-0080-4
Kivitz A, Cohen S, Dowd JE, et al. Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial. Clin Ther. 2006;28:1619–29.
doi: 10.1016/j.clinthera.2006.10.006
van den Bemt BJF, Gettings L, Domanska B, Bruggraber R, Mountian I, Kristensen LE. A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience. Drug Deliv. 2019;26:384–92.
doi: 10.1080/10717544.2019.1587043

Auteurs

Kathryn Bailey (K)

Healthcare at Home Ltd., Burton upon Trent, UK. kbailey@onerevelation.com.

Irina Mountian (I)

UCB Pharma, Brussels, Belgium.

Richard Bruggraber (R)

UCB Pharma, Slough, UK.

Kerri Sunderland (K)

UCB Pharma, Slough, UK.

Nicola Tilt (N)

UCB Pharma, Brussels, Belgium.

Boglarka Szegvari (B)

UCB Pharma, Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH